ELEthan Yichen Lee

Ethan Yichen Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ethan Yichen Lee has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

    by Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka

    Chronic hepatitis B remains a major contributor to liver‐related morbidity and mortality despite available effective antiviral therapies. Nucleos(t)ide analogs provide durable suppression of hepatitis B virus (HBV) replication but rarely achieve hepatitis B surface antigen (HBsAg) loss, and interferon‐based regimens are limited by modest efficacy and poor tolerability. Consequently, functional cure, defined as sustained HBsAg loss with undetectable HBV DNA after treatment, has become the central therapeutic goal. Recent advances highlight the promise of RNA‐targeting agents, including small interfering RNAs, antisense oligonucleotides, and RNA destabilizers, which directly reduce viral transcripts and antigen production. In parallel, immunomodulators such as pegylated interferon, checkpoint inhibitors, and therapeutic vaccines aim to restore HBV‐specific immunity. Emerging evidence shows that rationally designed combination regimens, integrating nucleos(t)ide analogs as a backbone with antigen‐lowering agents and immunotherapies, can synergistically enhance functional cure rates. As therapeutic strategies evolve, monitoring biomarkers beyond HBV DNA will be critical. Quantitative HBsAg reflects both covalently closed circular DNA and integrated HBV DNA activity, whereas hepatitis B core‐related antigens (HBcrAgs) provide complementary information on covalently closed circular DNA transcriptional activity. Together, these markers enable more precise assessment of treatment response, prediction of relapse risk, and evaluation of long‐term outcomes. In summary, the pursuit of functional cure in chronic hepatitis B is shifting toward multidrug strategies that combine potent viral suppression, antigen reduction, and immune restoration. Within this framework, the parallel monitoring of HBsAg and HBcrAg alongside HBV DNA will be indispensable for guiding therapeutic decisions, benchmarking clinical trial end points, and advancing personalized treatment strategies.

  • Open Access

    Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study

    by Shinya Kawamatsu, Kiran K. Rai, Vera Gielen, Amisha Patel, Olivia Massey, Seth W. Anderson, Yutaka Handa, Ethan Yichen Lee, Poppy Payne, Isabel Jimenez, et al.

    Nucleos(t)ide analogue (NA) therapy is the current standard of care for chronic hepatitis B (CHB) virus infection but rarely achieves functional cure, necessitating long‐term therapy, which often leads to nonadherence and increased treatment burden. This retrospective cohort study was designed to describe treatment discontinuation and adherence to second‐generation NAs among patients with CHB in Japan. We used the Japanese Medical Data Center Claims Database (JMDC Inc.) to identify adults with CHB who were newly initiated on a single‐agent, second‐generation NA between January 2007 and August 2023. Outcomes included treatment discontinuation and adherence, treatment restart after discontinuation, NA switching and factors associated with treatment discontinuation/adherence. Of the 2473 patients included in this study (mean age 49.9 years), 65.6% were male. The most common index NAs were entecavir (55.5%) and tenofovir alafenamide fumarate (TAF, 36.2%). Treatment discontinuation was observed in 20.3% of patients; mean time to discontinuation was 20.4 months. Of the patients who discontinued, 50.7% restarted NAs. Mean adherence (proportion of days covered [PDC]) was 0.87, and 81.2% of participants had PDC ≥ 80%. Age group 35–64 years, index treatment TAF and baseline hepatocellular carcinoma diagnosis were significantly associated with a decreased probability of treatment discontinuation and nonadherence. Although a high proportion of patients were persistent and adherent to NA treatment, there is a subgroup of patients whose needs are not met while receiving NA treatment, particularly in younger age groups. The results emphasise the need for alternative therapies with shorter, finite treatment durations to improve patient persistence, adherence and outcomes.